// added the section below on July 01 2024 // till here on July 01 2024

Metal and Lipid Nanoparticle Manufacturing Market

Metal and Lipid Nanoparticle Manufacturing Market by Service, Company Size, Type of Nanoparticles Manufactured, Scale of Operation, Type of End User and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2035

  • Lowest Price Guaranteed From USD 4,799

  • Pages
    197

  • View Count
    11932

Majority of big pharma players that offer a wide range off the shelf products and custom services associated with nanoparticles are headquartered in the US. Further, given the rising interest of developer companies to avail contract manufacturing services, such service providers are likely to witness lucrative market opportunities in the foreseen future

-CEO, Europe based Small Sized Company

Metal and Lipid Nanoparticle Manufacturing Market Overview

The metal and lipid nanoparticle manufacturing market (service) is estimated to be worth $2.1 billion in 2021 and is expected to grow at compounded annual growth rate (CAGR) of 8.6% during the forecast period. Over the past few decades, the pharmaceutical industry has witnessed significant growth, as also evident from the continuously growing pipeline of drug candidates that have been marketed or are being evaluated across several development stages. However, a recent study published in the journal of Analytical and Pharmaceutical Research has highlighted that around 90% of the candidates in the current preclinical development pipeline and more than 40% of the marketed pharmacological products are associated with concerns related to solubility / permeability. Further, it was observed that a pharmacological product became 10% less vigorous, each time, when mixed with another product, due to drug incompatibility.Therefore, players engaged in metal and lipid nanoparticle manufacturing market are actively trying to identify ways to improve / augment physiochemical properties and drug-like behavior of pharmacological products. Amidst other alternatives, the use of nanoparticles has garnered the attention of many drug developers. In fact, the novel vaccines developed to treat COVID-19 are enclosed within a layer of lipid nanoparticles; these molecules assist the delivery of active ingredients to the required site of action. Moreover, many drug developers are using lipid / metal nanoparticles to re-formulate existing product candidates in order to further improve their bioavailability / biocompatibility. However, for some of the nanoparticles having medical applications, the associated manufacturing processes are highly complex, capital-intensive and fraught with multiple challenges, such as need for specialized expertise (especially in case of lipid nanoparticles), lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. Considering the routine operations-related and technical challenges, an increased number of pharmaceutical companies have demonstrated the preferences to outsource their respective nanoparticle production operations to specialized service providers. 

There are numerous benefits of engaging contract development and manufacturing (CDMO) / contract manufacturing organizations (CMO) for nanoparticle manufacturing; for instance, contracting a supplier for medical grade nanoparticles enables sponsors to leverage new technologies (available with the service provider), access larger capacities and achieve greater operational flexibility. Presently, there are several contract manufacturers and technology providers, who claim to have the required capabilities to manufacture nanoparticles (lipid and metal nanoparticles). However, the global expertise and capabilities necessary for the production of GMP grade nanoparticles are currently limited. As a result, many companies offering contract manufacturing services for nanoparticles are actively trying to consolidate their presence in metal and lipid nanoparticle manufacturing market, by entering into various strategic alliances to broaden their respective service portfolios. It is also worth highlight that, recently, a number of deals were inked between vaccine developers and CMOs in order to cater the urgent need for nanoparticle-based solutions for the development of COVID-19 vaccines. Given the benefits of using nanoparticles to improve drug-like properties, we believe, that the demand for high quality nanoparticles is likely to drive considerable market growth within the specialty contract manufacturing market in the forecast period.

This image highlights the context of Nanoparticle Contract Manufacturing Market report. In addition to enhancing physiochemical characteristics of drugs, nanoparticles act as drug delivery systems; given their crucial role in development of COVID-19 vaccines, there is a surge in demand for such molecules, creating lucrative opportunities for stakeholders This image provides list of Nanoparticle Contract Manufacturers. At present, more than 50 companies across the globe claim to have the required capabilities to offer a range of services for the development and manufacturing of lipid / metal nanoparticles This image presents current market landscape of Nanoparticle Contract Manufacturers. Several CMOs have the necessary expertise to provide production services for different types of nanoparticles across varied scales of operations; such players cater to the needs of a number of end users

Key Companies Offering Services in Metal and Lipid Nanoparticle Manufacturing Market

Examples of key companies engaged in providing services in metal and lipid nanoparticle manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Ardena, CordenPharma, Curia, Evonik, LSNE Contract Manufacturing, Polymun and TechNanoIndia. This market report includes an easily searchable excel database of all the companies providing nanoparticles contract manufacturing, worldwide.

Recent Developments in Metal and Lipid Nanoparticle Manufacturing Market:

Several recent developments have taken place in the field of metal and lipid nanoparticle manufacturing market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In July 2023, DIANT® Pharma announced the acquisition of the DIANT® LiFT system by the FDA in order to advance its analytical and output standards across continuous manufacturing of lipid and polymer-based nanoparticles. 
  • In May 2023, Nanoform announced the renewal of its GMP license by Finnish Medicines Agency (FIMEA). Additionally, it started clinical API manufacturing of a blockbuster drugs. 
  • In June 2023, JSR Corporation inked a partnership with Hokkaido University for the production, sales and marketing of functional lipid nanoparticles for the drug delivery systems.
This image provides information about Key Insights Nanoparticle Contract Manufacturers. Most of the players offering contract services for nanoparticles to different end users are headquartered in North America and Europe; the US and Germany have emerged as the most prominent countries within these regions This image highlights competitive analysis of players engaged in the domain of Nanoparticle Manufacturing. In order to gain an edge in this competitive industry, nanoparticle contract manufacturers are continuously undertaking initiatives to upgrade their existing service offerings This image provides information about Go / No-Go Framework for Nanoparticle-based Therapeutics Developers. Built on our intellectual capital, we have proposed a proprietary framework to allow developers to decide whether to outsource manufacturing or keep it in-house; we expect majority of the small firms to outsource such operations

Scope of the Report

The “Metal and Lipid Nanoparticle Manufacturing Market by Company Size (Very Small Companies, Small Companies, Mid-Sized Companies, and Large Companies), Type of Nanoparticle(s) Manufactured (Lipid and Metal Nanoparticles), Scale of Operation (Preclinical, Clinical, and Commercial), Type of End User (Educational Institutions, Pharmaceutical Companies, Research Institutions, and Other End Users), and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa (MENA),  Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the contract service providers engaged in manufacturing of nanoparticles for the purpose of preclinical development, clinical research and commercialization. The market research report features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in metal and lipid nanoparticle manufacturing market.

Amongst other elements, the market report features:

  • A detailed overview  of the current market landscape of nanoparticle contract manufacturers, along with information on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized and large), location of headquarters, type of organization (CDMO and CMO), type of nanoparticle(s) manufactured (lipid and metal nanoparticles), location and number of manufacturing facilities, scale of operation (preclinical, clinical, and commercial), type of end user (educational institutions, pharmaceutical companies. research institutions, and other end users), type of service(s) offered, quality certifications and regulatory organizations. 
  • An in-depth analysis, highlighting  the contemporary market trends using six schematic representations, including [A] a bubble representation based on company size and type of organization, [B] a comparative world map representation, based on company size, location of the headquarters and type of nanoparticle(s) manufactured, [C] a stacked bar chart representation based on company size and scale of operation, [D] a heat map representation highlighting the regional distribution of developers engaged in metal and lipid nanoparticle manufacturing market,  [E] a 4D bubble analysis comparing the leading players engaged in metal and lipid nanoparticle manufacturing market, based on several relevant parameters (such as company size, type of nanoparticle(s) manufactured, number of manufacturing facilities, and number of service(s) offered), [F] a grid representation illustrating the distribution of nanoparticle contract manufacturers based several relevant parameters (such as type of organization, type of nanoparticle(s) manufactured, scale of operation, type of end user, and type of service(s) offered).
  • An in-depth company competitiveness analysis of nanoparticle contract manufacturers, based on several relevant parameters, such as company’s service strength (taking into consideration years of experience, type of organization, type of nanoparticle(s) manufactured, number of manufacturing facilities, scale of operation, type of end user and type of service(s) offered) and partnership strength (taking into consideration the number of partnerships and type of agreement).
  • Elaborate profiles of key players that offer contract manufacturing services for nanoparticle(s). Each profile features a brief overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, recent developments and an informed future outlook.
  • An analysis of recent partnerships inked between various stakeholders engaged in metal and lipid nanoparticle manufacturing market, during the period 2015-2021, based on several relevant parameters, such as year of partnership, type of partnership (company acquisitions, manufacturing agreements, mergers, product development agreements, product distribution agreements, technology integration agreements, and other agreements), type of partner, type of nanoparticle(s) manufactured, emerging focus area, seniority level of stakeholders, most active players (in terms of number of partnerships), type of agreement and regional distribution.
  • An insightful analysis, highlighting the various factors that need to be taken into consideration by nanoparticle(s) developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO. Further, the analysis highlights all the key parameters that must be considered by players based on company sizes (very small, small, mid-sized, and large), while taking the aforementioned decision.

One of the key objectives of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunity of the nanoparticle contract manufacturing market during the forecast period. We have also provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, over the forecast period 2021-2035. Additionally, the market report features the likely distribution of the current and forecasted opportunity across [A] company size (very small, small mid-sized, and large), [B] type of nanoparticle(s) manufactured (lipid and metal nanoparticles), [C] scale of operation (preclinical, clinical and commercial) and [D] type of end user (educational institutions, pharmaceutical companies, research institutions, and other end users), and [E] key geographical regions (North America, Europe, Asia, MENA, Latin America and rest of the world).  In order to account for future uncertainties in the market and add robustness to our forecast model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s evolution. The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in the industry. 

This image highlights the partnership activity undertaken by players engaged in Nanoparticle Contract Manufacturing. The growing interest is also evident from the rise in partnership activity; a major proportion of the deals were signed by companies based in North America This image provides information on the current and future market trends and potential growth of Nanoparticle Contract Manufacturing Market. Driven by the rising demand for drugs that can overcome the existing challenges associated with solubility, the nanoparticle contract manufacturing market is estimated to grow at an annualized rate of about 9%, till 2035 This image highlights the market segments of Nanoparticle Contract Manufacturing Market. The projected market opportunity is likely to be distributed across different scales of operations, company size and key geographical regions

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is nanoparticle contract manufacturing?

Answer: Nanoparticles contract manufacturing refers to the process of manufacturing nanoparticles by specific organizations which have the capability and expertise to provide nanoparticles for pharmaceutical applications.

Question 2: How big is the metal and lipid nanoparticle manufacturing market?

Answer: The metal and lipid nanoparticle manufacturing market size (services) is estimated to be worth $2.1 billion in 2021.

Question 3: What is the projected market growth of the metal and lipid nanoparticle manufacturing market?

Answer: The metal and lipid nanoparticle manufacturing market is expected to grow at compounded annual growth rate (CAGR) of over 8.6% during the forecast period 2021 - 2035.

Question 4: Who are the leading players in the metal and lipid nanoparticle manufacturing market?

Answer: Examples of key companies engaged in metal and lipid nanoparticle manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Ardena, CordenPharma, Curia, Evonik, LSNE Contract Manufacturing, Polymun and TechNanoIndia.

Question 5: How many companies are currently engaged in metal and lipid nanoparticle manufacturing market?

Answer: Over 50 CMOs are currently engaged in the metal and lipid nanoparticle manufacturing market.

Question 6: How many companies outsource manufacturing of nanoparticles to CMOs engaged in the metal and lipid nanoparticle manufacturing market?

Answer: Currently, 60% of the companies outsource manufacturing of nanoparticles to players engaged in metal and lipid nanoparticle manufacturing market.

Question 7: Which region is the hub for CMOs engaged in metal and lipid nanoparticle manufacturing market?

Answer: North America emerged as the hub for CMOs engaged in metal and lipid nanoparticle manufacturing market, with close 60% of the players established in the region.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com